The UAE has become the second country in the world to approve the use of Wegovy (semaglutide), an oral once-daily pill, to treat weight loss in adults with obesity and reduce the risks of heart conditions in high-risk patients.
Developed by Novo Nordisk, the treatment belongs to the GLP-1 receptor agonist class and works alongside a reduced-calorie diet and increased physical activity.
Making the announcement on Monday, the Emirates Drug Establishment said the move cements the UAE’s efforts to promote awareness around the importance of early obesity management and reducing associated health complications.
The cost of the pill was not unveiled.
The regulatory approval was based on the results of clinical studies demonstrating the treatment’s effectiveness in supporting weight reduction and its role in reducing the risk of major adverse cardiovascular events among high-risk patients.
'Dubai-it' initiative to embed Dubai’s work philosophy across generations
Dubai Police, RTA discuss measures to reduce heavy vehicle accidents
Dubai Holding's 'Gift It Forward' distributes repurposed items worth AED 22 million
UAE President calls for stronger global cooperation at G7 Summit
